您当前的位置：首页 > 主题内容 > 临床麻醉 > 专家评述
氯胺酮对大鼠肺组织及外周血白细胞磷酸二酯酶活性的影响
Effect of ketamine on the activities of phosphodiestrases(PDE) in lung tissue and leukocyte of rats.ZHOU-Hai yan,ZHANG-Xiu lai,ZHOU Yi-feng,et al. Department of anesthesiology,The second Affiliated Hospital,Medical College of Zhejiang University,Hangzhou 310009,China 【Abstract】Objective To investigate the effect of ketamine on the activities of phosphodiestrases in lung tissue and leukocyte of rat. Methods Twenty rat were randomly divided into ketamine group(n=10) and control group(n=10). In ketamine group，ketamine 10mg/kg was injected intraperitoneal. The PDE activities were detected by HPLC. Results The phosphodiesterase activities in lung tissue and leukocyte in ketamine group were both lower than those in control group (P＜0.01﹚. Conclusions Ketamine can decrease phosphodiesterases activities in lung tissue and leukocyte of rats,thus reduce the resistance of airway. 【Keywords】 ketamine；lung；leucocyte；phosphodiesterase 材料与方法 实验材料 （1）实验动物：雄性Sprague-Dawley大鼠20只，体重140~ 实验方法 大鼠随机分为对照组和氯胺酮组，每组10只。氯胺酮组：腹腔内注射氯胺酮麻醉剂量10mg/kg，对照组以等量的生理盐水。30 min后股动脉放血处死动物，收集血液，分离出外周血白细胞，超声破碎法制成酶样品。同时剪开胸腔，用生理盐水从下腔静脉灌洗，去除肺组织中残余血，剪取肺组织25mg，在电动玻璃匀浆器中制成匀浆，作为酶样品。两种酶样品均进行蛋白定量。 酶反应在含Mg2+、Ca2+的PBS液中进行，反应管中包含酶样品20μl、cAMP1μmol/L，反应液总量200μl，反应管置于 标准曲线绘制 取cAMP标准品溶于含Mg2+、Ca2+的PBS液，配制成浓度为0.1、0.2、0.4、0.6、0.8、1.0μmol/L，于相同条件下进行测定，以浓度（C）为横坐标，cAMP的峰面积（RA）为纵坐标, cAMP的标准曲线RA= 统计学分析 数据用x ±ｓ表示，数据间比较采用两样本均数ｔ检验, P＜0.01为统计学有意义。 结 果 氯胺酮对大鼠外周血白细胞PDE活性的影响 氯胺酮可抑制大鼠外周血白细胞PDE水解cAMP的活性。氯胺酮组PDE活性为(181±52) pmol.mg-1.min-1，与对照组(273±61) pmol.mg-1.min-1相比，P＜0.01。 氯胺酮对大鼠肺组织PDE活性的影响 氯胺酮可抑制大鼠肺组织PDE水解cAMP的活性。氯胺酮组PDE活性为(212±75)pmol.mg-1.min-1，与对照组(359±98) pmol.mg-1.min-1相比，P＜0.01。 大鼠外周血白细胞及肺组织cAMP－PDE色谱图见图1。
参考文献 1 Sato T, Hirota K, Matsuki A, et al. Ketamine inhibits the tonic response to carbachol and histamine in the guinea pig trachea. Eur J Anaesthesiol, 1998 ,15: 486-492. 2 Cheng EY, Mazzeo AJ, Bosnjak ZJ, et al. Direct relaxant effects of intravenous anesthetics on airway smooth muscle. Anesth Analg，1996, 83: 162-168. 3 Mark A. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis, 2002, 57: 48–64. 4 James J, Peter C, Julie N, et al. Anti-inflammatory effects of theophylline:modulation of cytokine production. Ann Allergy Asthma Immunol, 1996, 77:34–38. 5 Torphy TJ. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med，1998, 157: 351-370. 6 Essayan DM, Huang SK, Kagey-Sobotka A, et al. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J Allergy Clin Immunol，1997，99: 28-37. 7 Goncalves de Moraes VL, Singer M, Vargaftig BB, et al. Effects of rolipram on cyclic AMP levels in alveolar marcrophages and lipopolysaccharide-induced inflammation in mouse lung. Br J Pharmacol, 1998, 123: 631-636. 8 Mahinaz H, Bpharm M, Alexandra T, et al. Current drug treatment of asthma. Hospital Pharmacist, 2001, 8:241-247. 9 Mark A. Phosphodiesterase 4 inhibitors and the treatment of asthma. Drugs, 2000, 59: 193-212. 10 Thomas J, Carver M, Haisch C, et al. Diffirential effects of intravenous anesthetic agents on cell-mediated immunity in the Rhesus monkey. Clin EXP Immunol, 1982, 47:457-466. |
|
|
